MRNA is poised for a comeback. This is the first stock i ever bought and invested in, its one of the reasons why i started trading, and im glad to introduce it back into my investment portfolio.
Healthcare is recession proof, it can act as a great hedge against big tech, it can be used for diversification, it can benefit as we start a rotation transition, the company has a lot of potential outside COVID with its mRNA technology, and the technicals just look great!
MRNA is in a really great spot from a technical perspective and for a relatively young company, i think they are making import scale up moves that will help in the long-term 👇
It sucks to see highly esteemed scientist Bob Langer retire from the board but after looking into David Rubenstein's resume, i think he can really help scale up Moderna with his multitude experience in VC, politics and business and well sometimes you just need that for a company to grow 🤷
We are holding a multitude of key areas here on the daily chart and we have performed well for the past couple earnings along with being well below the 144$ average price tag by analysts. Playing earnings is always very risky so I'm sticking to shares only in my investment portfolio but i do think the upside potential far outweighs the downside here.
Only 4 more days, let's hope for a good one. 😎
Comment
WOW, what a sell off. This one is disappointing, the technical showed so much potential but sometimes the trades we plan out just don't play out how we want them too. Moderna actually reported decent revenue numbers but the past isnt as important as the future when it comes to earnings and the forwards guidance was poor. Its clear the COVID sales are slowing and they have forecasted lower sales in 2024 and as a result we have dumped over 21% on the day. YIKES! 😭
The technicals have been violated and the fundamentals point towards a slower year. The trade is no longer valid.
I am however still a Longterm believer in Moderna as i am a firm believer in the mRNA techology and have hope in the progress we are making.
"During the second quarter, we marked the approval of our second mRNA product and significantly lowered our operating costs," Chief Executive Stephane Bancel said in a statement. "We remain focused on execution for the 2024-25 COVID season and the launch of our (respiratory syncytial virus) vaccine in the US."
And i am I am especially interested in seeing how David Rubenstein can help scale the company. we went from 45 B to a 36B market cap and honestly i think cause the markets are weak it was a bit of an overreaction. We got flu season coming in during the second half of the year and i think once we bottom out we can slowly make our way up again to 115$.
Comment
alright so interesting day today. looked like we were ready to bounce and saw some green but closed red instead. The markets look weak and further downside is likely to come. The daily chart is looking oversold to me and i think we are due for a bounce soon 😤
i think if we can hold this area we can deadcat and fill the gap left around 92.50$, i will consider a option position to capture this move
after such i expect us to drop down to 72$ and start bottoming out at which point i will short MRNA
i will gladly buy shares at our lower support
Comment
establishing a base here, this looks ready to bounce
Comment
holding this area of consolidation here
Comment
NIce little bounce expect us to fill in gap here
Comment
we called the bounce, love to see it ! would like to see that gap fill for another 4.3%
Comment
upper gap failed to fill and as expected a dead cat has manifested, expect price to drop as low as 70$
Comment
expecting price to continue to drop and level out
Comment
NICE! 1st target hit, would like to see the lower gap fill and price touch the 70$ mark
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.